Optimal Management of Clinical Stage I Testis Cancer: One Size Does Not Fit All
Cet article passe en revue les travaux récents justifiant le recours à une surveillance active chez les patients atteints d'un cancer du testicule de stade I
The optimal management for clinical stage (CS) I testicular germ cell tumors (GCTs) is controversial. Simply put, the efficacy of cisplatin-based chemotherapy cures nearly 100% of both seminoma (SEM) and nonseminomatous germ cell tumors (NSGCTs) that relapse after either early definitive treatment or active surveillance. Since no trial data provide evidence for the superiority of one approach over another, personal belief, institutional preference, or national consensus guides the treatment choice. In the article that accompanies this editorial, Nichols et al1 aim to end the debate, arguing that active surveillance should be recommended to all patients with CS I testicular GCT. We do not believe that the evidence warrants this universal guideline...
Journal of Clinical Oncology , éditorial en libre accès, 2013